Concepts (128)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Non-Small-Cell Lung | 9 | 2024 | 106 | 2.100 |
Why?
|
| Lung Neoplasms | 10 | 2024 | 247 | 2.040 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2018 | 7 | 0.540 |
Why?
|
| Inflammation Mediators | 1 | 2018 | 37 | 0.530 |
Why?
|
| Carcinoma, Squamous Cell | 5 | 2019 | 70 | 0.530 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2018 | 42 | 0.520 |
Why?
|
| Pneumonectomy | 2 | 2015 | 34 | 0.510 |
Why?
|
| Biomarkers | 1 | 2018 | 294 | 0.480 |
Why?
|
| Neoadjuvant Therapy | 3 | 2016 | 23 | 0.470 |
Why?
|
| Social Class | 1 | 2014 | 24 | 0.410 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2021 | 105 | 0.390 |
Why?
|
| Chemoradiotherapy | 5 | 2016 | 17 | 0.380 |
Why?
|
| Aged | 11 | 2024 | 4000 | 0.350 |
Why?
|
| Immunotherapy | 2 | 2021 | 27 | 0.340 |
Why?
|
| Female | 14 | 2024 | 6974 | 0.330 |
Why?
|
| Male | 13 | 2024 | 6815 | 0.320 |
Why?
|
| Neoplasm Staging | 7 | 2024 | 168 | 0.310 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2021 | 11 | 0.300 |
Why?
|
| Humans | 17 | 2024 | 12240 | 0.290 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2019 | 40 | 0.280 |
Why?
|
| Oropharyngeal Neoplasms | 2 | 2019 | 9 | 0.270 |
Why?
|
| Head and Neck Neoplasms | 2 | 2021 | 57 | 0.270 |
Why?
|
| Antineoplastic Agents | 2 | 2022 | 99 | 0.270 |
Why?
|
| Middle Aged | 9 | 2024 | 4043 | 0.260 |
Why?
|
| Biomarkers, Tumor | 2 | 2021 | 101 | 0.260 |
Why?
|
| Adenocarcinoma | 2 | 2018 | 61 | 0.240 |
Why?
|
| Body Composition | 1 | 2024 | 43 | 0.210 |
Why?
|
| Prognosis | 3 | 2021 | 363 | 0.200 |
Why?
|
| Survival Rate | 3 | 2018 | 152 | 0.190 |
Why?
|
| Programmed Cell Death 1 Receptor | 2 | 2021 | 9 | 0.190 |
Why?
|
| Maytansine | 1 | 2022 | 2 | 0.180 |
Why?
|
| Immunoconjugates | 1 | 2022 | 6 | 0.180 |
Why?
|
| Body Weight | 2 | 2024 | 72 | 0.180 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2021 | 69 | 0.170 |
Why?
|
| Neoplasms | 1 | 2022 | 94 | 0.170 |
Why?
|
| Autoantibodies | 1 | 2021 | 29 | 0.160 |
Why?
|
| Retrospective Studies | 4 | 2019 | 1467 | 0.160 |
Why?
|
| Databases, Factual | 3 | 2019 | 156 | 0.160 |
Why?
|
| Breast Neoplasms | 1 | 2022 | 195 | 0.160 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2017 | 85 | 0.150 |
Why?
|
| Human papillomavirus 16 | 1 | 2019 | 6 | 0.150 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2019 | 26 | 0.150 |
Why?
|
| Tongue Neoplasms | 1 | 2018 | 10 | 0.140 |
Why?
|
| Cohort Studies | 3 | 2019 | 827 | 0.140 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2018 | 6 | 0.140 |
Why?
|
| Carcinoma, Large Cell | 1 | 2018 | 7 | 0.140 |
Why?
|
| ErbB Receptors | 1 | 2018 | 31 | 0.130 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2018 | 29 | 0.130 |
Why?
|
| Proteomics | 1 | 2018 | 39 | 0.130 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2019 | 165 | 0.130 |
Why?
|
| Mutation | 1 | 2018 | 175 | 0.130 |
Why?
|
| Age Factors | 2 | 2018 | 350 | 0.130 |
Why?
|
| Leukocyte Count | 1 | 2017 | 35 | 0.130 |
Why?
|
| Lymphocytes | 1 | 2017 | 30 | 0.120 |
Why?
|
| Neutrophils | 1 | 2017 | 58 | 0.120 |
Why?
|
| Quality of Life | 1 | 2019 | 261 | 0.120 |
Why?
|
| Adult | 3 | 2019 | 3557 | 0.120 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 726 | 0.120 |
Why?
|
| Treatment Outcome | 5 | 2021 | 1478 | 0.110 |
Why?
|
| Carcinoma | 2 | 2015 | 34 | 0.110 |
Why?
|
| Prospective Studies | 1 | 2018 | 817 | 0.110 |
Why?
|
| United States | 2 | 2019 | 989 | 0.110 |
Why?
|
| Prostaglandins | 1 | 2014 | 2 | 0.110 |
Why?
|
| Induction Chemotherapy | 1 | 2014 | 8 | 0.100 |
Why?
|
| Cancer Care Facilities | 1 | 2014 | 6 | 0.100 |
Why?
|
| Academies and Institutes | 1 | 2014 | 6 | 0.100 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2014 | 14 | 0.100 |
Why?
|
| Parotid Gland | 1 | 2014 | 11 | 0.100 |
Why?
|
| Lymphatic Metastasis | 1 | 2014 | 51 | 0.100 |
Why?
|
| Health Services Accessibility | 1 | 2014 | 43 | 0.100 |
Why?
|
| Logistic Models | 1 | 2014 | 196 | 0.100 |
Why?
|
| Prevalence | 1 | 2014 | 175 | 0.100 |
Why?
|
| Aged, 80 and over | 1 | 2018 | 2152 | 0.090 |
Why?
|
| Therapies, Investigational | 1 | 2011 | 5 | 0.090 |
Why?
|
| Esophageal Neoplasms | 1 | 2011 | 22 | 0.090 |
Why?
|
| Combined Modality Therapy | 3 | 2019 | 143 | 0.080 |
Why?
|
| Patient Selection | 2 | 2021 | 111 | 0.060 |
Why?
|
| Disease-Free Survival | 2 | 2018 | 66 | 0.060 |
Why?
|
| Lymph Nodes | 2 | 2016 | 38 | 0.060 |
Why?
|
| Pemetrexed | 2 | 2015 | 4 | 0.060 |
Why?
|
| Body Mass Index | 1 | 2024 | 221 | 0.050 |
Why?
|
| Tumor Microenvironment | 1 | 2022 | 12 | 0.050 |
Why?
|
| Cetuximab | 1 | 2021 | 2 | 0.040 |
Why?
|
| Phototherapy | 1 | 2021 | 17 | 0.040 |
Why?
|
| B7-H1 Antigen | 1 | 2021 | 4 | 0.040 |
Why?
|
| Antigens, Neoplasm | 1 | 2021 | 22 | 0.040 |
Why?
|
| Observer Variation | 1 | 2021 | 47 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2021 | 99 | 0.040 |
Why?
|
| Genetic Heterogeneity | 1 | 2019 | 5 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 28 | 0.040 |
Why?
|
| Reference Values | 1 | 2019 | 103 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2018 | 19 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 1 | 2018 | 34 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2019 | 295 | 0.030 |
Why?
|
| Papillomaviridae | 1 | 2016 | 5 | 0.030 |
Why?
|
| Papillomavirus Infections | 1 | 2016 | 8 | 0.030 |
Why?
|
| Radiation Pneumonitis | 1 | 2015 | 2 | 0.030 |
Why?
|
| Hemoptysis | 1 | 2015 | 4 | 0.030 |
Why?
|
| Esophagitis | 1 | 2015 | 5 | 0.030 |
Why?
|
| Etoposide | 1 | 2015 | 15 | 0.030 |
Why?
|
| Carboplatin | 1 | 2015 | 11 | 0.030 |
Why?
|
| Chest Pain | 1 | 2015 | 8 | 0.030 |
Why?
|
| Cough | 1 | 2015 | 7 | 0.030 |
Why?
|
| Paclitaxel | 1 | 2015 | 25 | 0.030 |
Why?
|
| Radiation Injuries | 1 | 2015 | 15 | 0.030 |
Why?
|
| Dyspnea | 1 | 2015 | 22 | 0.030 |
Why?
|
| Young Adult | 1 | 2018 | 863 | 0.030 |
Why?
|
| Adolescent | 1 | 2018 | 989 | 0.030 |
Why?
|
| Palliative Care | 1 | 2015 | 53 | 0.030 |
Why?
|
| Neoplasm, Residual | 1 | 2015 | 5 | 0.030 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2015 | 4 | 0.030 |
Why?
|
| Lymph Node Excision | 1 | 2015 | 15 | 0.030 |
Why?
|
| Radiotherapy Dosage | 1 | 2015 | 42 | 0.030 |
Why?
|
| Glutamates | 1 | 2014 | 3 | 0.030 |
Why?
|
| Guanine | 1 | 2014 | 3 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2015 | 125 | 0.030 |
Why?
|
| Taxoids | 1 | 2014 | 4 | 0.030 |
Why?
|
| Cyclooxygenase 2 | 1 | 2014 | 18 | 0.030 |
Why?
|
| Pyrroles | 1 | 2014 | 15 | 0.030 |
Why?
|
| Sulfonamides | 1 | 2014 | 22 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2014 | 84 | 0.030 |
Why?
|
| Patient Readmission | 1 | 2015 | 48 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2014 | 166 | 0.030 |
Why?
|
| Length of Stay | 1 | 2015 | 126 | 0.030 |
Why?
|
| Choice Behavior | 1 | 2011 | 19 | 0.020 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2011 | 14 | 0.020 |
Why?
|
| Medical Oncology | 1 | 2011 | 23 | 0.020 |
Why?
|
| Disease Progression | 1 | 2011 | 290 | 0.020 |
Why?
|